Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | TLR2 | O60603 | 3/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437099 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL29401421 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL31437131 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL3728827 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL25357584 | 0.97 | MDM2 (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL25357589 | 0.97 | MDM2 (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL5495444 | 0.92 | FOLH1 (0.57) | KMT2AMDM2 | |
| SCHEMBL260631 | 0.92 | KMT2A (0.66) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL178698 | 0.92 | KMT2A (0.66) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL178733 | 0.92 | KMT2A (0.66) | KMT2AMDM2TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| CN-115819511-A | Preparation method and application of giant salamander hydrolyzed collagen active peptide | 广州远想医学生物技术有限公司 | 2023-03-21 | — | — | CN | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | UNIVERSITAET WIEN (AT) | 2026-04-30 | — | — | US | disclosed |
| EP-4729529-A1 | PREPARATION OF PEPTIDE INHIBITOR OF INTERLEUKIN-23 RECEPTOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-3319984-B1 | TAU-BINDING ANTIBODIES | UCB Biopharma SRL (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-22 | — | — | US | disclosed |
| EP-4676595-A1 | INTERLEUKIN-23 RECEPTOR ANTAGONIST PEPTIDES FOR USE IN THE TREATMENT OF PSORIASIS | Janssen Pharmaceutica NV (BE) | 2026-01-14 | — | — | EP | disclosed |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-8293870-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2399599-A2 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100197607-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2010-08-05 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20090275520-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2009-11-05 | — | — | US | disclosed |
| US-7524926-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101146545-A | Mucin hypersecretion inhibitors based on the structure of MANS and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | IL23R, IL17A, IL36G | KMT2A 958/4885MDM2 4433/4885TLR2 1423/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | KMT2A 1851/4885MDM2 3462/4885TLR2 133/4885 |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL36G, IL15RA | KMT2A 3239/4885MDM2 3323/4885TLR2 173/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | KMT2A 4698/4885MDM2 3296/4885TLR2 1030/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | KMT2A 4176/4885MDM2 1236/4885TLR2 883/4885 |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | OXTR, CRH, TRHR | KMT2A 3331/4885MDM2 3967/4885TLR2 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.